Trial Profile

Phase IIb/III Parallel-arm, Random., Active-controlled, Double-blind, Double-dummy, Multicenter, Non-inferiority Study in Patients With RVVC to Compare Efficacy, Safety and Tolerability of Topically Administered ProF-001 to Oral Fluconazole

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 14 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Clotrimazole/diclofenac (Primary) ; Clotrimazole/diclofenac (Primary) ; Fluconazole
Indications Vulvovaginal candidiasis
Focus Registrational; Therapeutic Use
Sponsors ProFem

18 Aug 2023 Results assessing health-related QoL in women with RVVC using validated questionnaires before and after treatment published in the Mycoses
07 Mar 2023 This trial has been completed in Slovakia (End Date: 18 Nov 2022) according to European Clinical Trials Database record.
01 Mar 2023 This trial has been completed in Austria (End Date: 18 Nov 2022), according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com